Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: SPOR Innovative Clinical Trials (iCT)

University of Ottawa

$100,000.00

Catalyzing registry-based randomized comparative effectiveness trials for inherited metabolic diseases in children: establishing a core outcome set and data collection tools

EF 2016-17

Résumé
Inherited metabolic diseases (IMD) are individually rare genetic diseases that together affect about 3,000 Canadian children. These diseases are characterized by high health care needs and substantial caregiver burden. There are important questions about the effectiveness of treatments for IMD that have not been addressed in high quality clinical trials. This is in part because of challenges in conducting randomized trials for diseases that are rare. The "registry-based randomized trial" design presents a unique opportunity to help with these evidence gaps. It involves the collection of meaningful and standardized outcomes on an on-going basis for a representative group of patients enrolled in a registry. It will allow researchers to more rapidly develop and implement randomized trials that compare treatments for rare diseases so that patients, health care providers, and policy makers will know which therapies work best. The purpose of this research is to further develop an existing Canada-wide cohort study of children with IMD, the Canadian Inherited Metabolic Diseases Research Network (CIMDRN) so that it can be used to conduct registry-based randomized trials. We will do this by: 1. Working together with patients and families, health care providers, policy makers and researchers to agree on a set of outcomes that will be most meaningful for evaluating treatments for IMD. 2. Identifying the best way to measure the agreed outcomes. This will include measurements carried out by health care providers and measurements that can be reported by patients or their families. 3. Pilot testing the outcomes and measures in five metabolic clinics, with providers and patients/families. The results will help us to continue to work together to measure these standard outcomes on an on-going basis with a larger group of patients with IMD; and to develop new randomized trials that compare treatments, ultimately improving care and health.
Programme
Catalyst Grant: SPOR Innovative Clinical Trials (iCT)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
359015
Name
Potter Elizabeth K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Health systems / services
Prcname2
Catalyst Grant SPOR Innovative Clinical Trials
Projecttitle
Catalyzing registry-based randomized comparative effectiveness trials for inherited metabolic diseases in children: establishing a core outcome set and data collection tools
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: SPOR Innovative Clinical Trials (iCT)
Keyworddelim
Inherited Metabolic Disease; Pediatrics; Pragmatic Trial; Rare Disease; Registry; Registry-Based Randomized Trial
Abstract
Inherited metabolic diseases (IMD) are individually rare genetic diseases that together affect about 3,000 Canadian children. These diseases are characterized by high health care needs and substantial caregiver burden. There are important questions about the effectiveness of treatments for IMD that have not been addressed in high quality clinical trials. This is in part because of challenges in conducting randomized trials for diseases that are rare. The "registry-based randomized trial" design presents a unique opportunity to help with these evidence gaps. It involves the collection of meaningful and standardized outcomes on an on-going basis for a representative group of patients enrolled in a registry. It will allow researchers to more rapidly develop and implement randomized trials that compare treatments for rare diseases so that patients, health care providers, and policy makers will know which therapies work best. The purpose of this research is to further develop an existing Canada-wide cohort study of children with IMD, the Canadian Inherited Metabolic Diseases Research Network (CIMDRN) so that it can be used to conduct registry-based randomized trials. We will do this by: 1. Working together with patients and families, health care providers, policy makers and researchers to agree on a set of outcomes that will be most meaningful for evaluating treatments for IMD. 2. Identifying the best way to measure the agreed outcomes. This will include measurements carried out by health care providers and measurements that can be reported by patients or their families. 3. Pilot testing the outcomes and measures in five metabolic clinics, with providers and patients/families. The results will help us to continue to work together to measure these standard outcomes on an on-going basis with a larger group of patients with IMD; and to develop new randomized trials that compare treatments, ultimately improving care and health.
Competitiondate
201609
Approvedterm2
1 yr 0 mth
Pinamesdelim
Potter, Elizabeth K; Clifford, Tammy J; Pallone, Nicole; Stockler, Sylvia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~